MMJ International Holdings, the premier medical cannabis research company, is advancing the science of medical marijuana legally through patient clinical research and the operation of medical cannabis healthcare businesses, announced that its affiliate, MMJ Bioscience, has finalized a partnership agreement with Terra Life Science group, a private Canadian based pharmaceutical manufacturer, to produce cannabis medicines for the groups FDA approved studies.
Last weeks announcement by Attorney General Sessions on the recision of the Cole Memorandum uniquely positions MMJ International Holdings as one of the only privately help companies pursuing the legal regulatory guidelines designated by the federal government for approval of a cannabis medicine.
The Guyana Cancer Institute believes that public awareness over the years has been paying off, but says it is too early to calculate whether there is a decline in the number of cases. Chakraborty said he saw about 75 to 80 cervical cancer patients last year and they are all still alive, but they need at least five years to determine their survival rate. He added that the Institute has observed that persons are turning up with cervical cancer in its earlier stages. "In the beginning, women were coming in the late stages but slowly and gradually through awareness efforts, there are less and less persons with higher stages of cancer," he said.
The Medical Director of the Cancer Institute said "the statistical data is not yet mature" but the number of cervical cancer patients he has been seeing in late stage three and stage four is showing signs of decline. "I can say one thing definitely- that the number of patients I used to see in advanced stages- stage three, stage four- right now we are seeing more in lesser advanced stages that stage four. There was a time when almost every patient I used to see I would find them in advanced stage three or event stage four," he said, adding they would not have taken the treatment and bleeding for several years.
Tim Moynahan, MMJ BioSciences chairman stated, ''The seasoned leadership team at MMJ BioSciences understands and executes its progressive development strategy in a legal, regulatory and fiscally responsible manner. Our company's success is the result of our focus on identifying patient medical needs and addressing these patients needs by developing FDA approved medicines from the cannabis plant.''
Tim Moynahan further stated, ''We are excited to be a partner with Terra Life Sciences. This agreement enables MMJ BioScience with a significant product development capability. We anticipate a number of important synergies between the two companies that will be addressing patients needs with MMJ BioScience's U.S. Food and Drug Administration (FDA) multiple sclerosis study beginning soon.''
Dr. Bianca Weinstock-Guttman, MMJ BioScience's principal investigator is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.
In late 2017 MMJ BioScience had submitted an application with the United States Food and Drug Administration (FDA) for approval of a new pharmaceutical drug. As a result of FDA application and Terra Life Sciences partnership, MMJ Bioscience now will offer excellence in cannabinoid medicine manufacturing that solves dosing issues by utilizing various delivery systems such as softgel pills, liquids, topical sprays and liposomes, with capabilities for quick release, sustained release and targeted release of cannabinoid medicines. Unlike other cannabis-type medicines, MMJ BioScience's medicine is plant derived. When approval is received from the FDA the new medicine would be on sale across America as an approved drug.
Cancer patients were Tuesday warned against relying on herbal medicine to cure the dreaded disease, even as the Guyana Cancer Institute showed off modern radiation technology that targets tumors and does not damage nearby organs.
The Institute's Director of Outreach, Dr. Syed Mujahid Ghazi said he has nothing against herbal and spiritual approaches, but at the same time he appealed to cancer patients and their relatives not to abandon conventional therapies.
"When they come to us after six months or five months, they are at a higher stage where they cannot come back and we see it every year. Every year, I lose three or four women. I am telling you, last year I lost three of my breast cancer patients because they were distracted from the treatment," he said.
He used the opportunity to appeal to Guyanese businesses to fund care and treatment of cancer patients at the Cancer Institute of Guyana.
Saying millions of dollars have been spent on research and development of treatments, he urged patients to ignore those who warn them that chemotherapy and radiation therapy will kill or burn them. "I beg people, I request of people if you want to advise somebody, advise them you can use them together with the treatment; you can add it but for God's sake don't tell people don't do the treatment," he said.
Ghazi and Medical Director and Consultant Oncologist of the Cancer Institute of Guyana, Dr. Sayan Chakraborty used the start of Cancer Awareness Month to call on women to take advantage of free pap smears in January and referral for treatment if necessary. "When people come in here, we try to help them and, if not, we have a strong partnership with the Department of Oncology (at the Georgetown Public Hospital Corporation)," Ghazi said.
Gahzi said the Cancer Institute was receiving full support by the Ministry of Health and more women have been turning out at rural treatment centres.
The Cancer Institute of Guyana boasts that it now has new and modern technology- a brachytherapy machine- to destroy cancer tumors without damaging nearby organs. "This new machine can pinpoint treatment to tumors only and provide safety to normal structures," Chakraborty said.
Acquired three months ago, the brachytherapy machine is already registering a "fantastic response" among the 20 patients who have received that focused radiation therapy which costs GY$300,000 in Guyana compared to GY$1 million n the Caribbean.
The Cancer Institute of Guyana is receiving support from the Healthy Caribbean Coalition and the government of Australia.
MMJ BioScience's expected approval by the FDA for its new medicine would have a major impact on the state to state federally illegal cannabis industry. In addition to Attorney General Sessions recent recision of the Cole Memorandum the FDA had also issued several cease and desist letters to firms that are marketing unapproved cannabinoid products. Whereas non-pharmaceutical companies cannot export their products across state lines, MMJ BioScience would be able to sell its medicine in pharmacies once prescribed by physicians.
The MMJ Group is focused on collaborative scientific research projects and following the FDA guidelines in beginning its clinical trials to fully explore the potential of cannabis medicine for progressive multiple sclerosis and Huntington's patients.